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EDITORIAL REVIEW
Focal and segmental glomeruloscierosis: Analogies to
atherosclerosis
Many experimental models of glomerular injury, such as
normal aging, renal ablation, streptozotocin-induced diabetic
nephropathy, and nephrotoxic serum nephritis (NSN) progress
to focal and segmental glomeruloscierosis (FSGS). Recently,
Grond, Van Goor and Elema in a brief report [11, speculated
that certain histologic features accompanying FSGS [segmental
glomerular accumulation of serum proteins, the presence of
lipids (primarily cholesterol and cholesterol esters), and mac-
rophages] strikingly resemble the lesion of atherosclerosis and
may indicate a parallel pathogenesis.
In atherogenesis, fatty streaks may develop into fibrous
plaques with necrotic, lipid-rich cores surrounded by vascular
smooth muscle cells (VSMC) and connective tissue [21. In
reviewing this process, Stary [3] noted that the arterial intima
becomes as thick as the media and is composed of VSMC,
elastic and collagen fibers, and glycosaminoglycans lying be-
neath the endothelium. These expanded intimas contained
isolated macrophage foam cells and, with time, lipid-filled
VSMC and foci of necrosis appear. The corresponding coun-
terparts in FSGS include mesangial expansion with mesangial
cell (MC) proliferation, mesangial foam cell accumulation,
deposits of amorphous debris, necrosis of tissue, and eventual
sclerosis.
Central to this analogy between the atherosclerotic and FSGS
process is the origin and functional properties of the glomerular
MC. Glomerular MC and VSMC are closely related in terms of
origin [4] microscopic anatomy and histochemistry [5], and
contractility [6]. In addition, it has been demonstrated, with
regard to regulation of VSMC proliferation, that heparin inhib-
its the growth of this cell type in vivo [7. 81 and in vitro [9, 10].
More recently, Castellot et al [11], have also shown that
heparin, likewise, inhibits glomerular MC in culture. The mes-
angium has been shown to contain at least two functionally
distinct subgroups of cell types. One resembles a macrophage
and the other a VSMC. In reviewing this subject, Striker and
Striker [12] noted that 3 to 5% of the total cells in the
mesangium are bone marrow derived and are responsible for
phagocytosis of substances entering the mesangium (such as
immune complexes). These macrophage-like MC have been
shown to bear the Ia and common lymphocyte (CL) antigens.
which are both indicative of a hematopoietic derivation for
these cells [12]. The second type of cell found in the mesangium
is smooth muscle-like and is probably derived from the para-
glomerular mesoderm [12]. These cells have been found to have
many common properties with VSMC including: angiotensin
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(All) receptors; calcium-dependent contractile response to sev-
eral mediators (All, arginine vasopressin, platelet-activating
factor); and a proliferative response to platelet- and macro-
phage-derived products [12].
The analogous pathophysiologic mechanisms between these
two processes are discussed below.
Hypertension and vascular stress
Endothelial injury or dysfunction, as the initial lesion in
atherosclerosis, has been a popular concept, because different
experimental models of endothelial damage cause proliferation
of underlying VSMC [7, 8]. It has been widely believed that
hypertension directly augments atherosclerosis by increased
hydraulic stress on the vessel wall, since lesions more fre-
quently occur at branch points in the vasculature where there is
a greater amount of shearing forces [13]. However, McGill [2]
argues that vasoactive hormonal activity, in association with
the elevated blood pressure, may be an independent athero-
genie factor. Thus, there is some uncertainty as to whether
there is some component of hypertensive pathophysiology
other than blood pressure that may be atherogenic [2].
Brenner and his colleagues [14] have formulated a role for
hemodynamically-mediated glomerular injury in the pathogen-
esis of progressive glomerular sclerosis. Elevated intrarenal
pressures and flows are seen not only in remnant kidneys after
surgical nephrectomy but also in other models of experimental
glomerular disease. These hyperfunctioning glomeruli in ab-
lated animals, and presumably in the other models, undergo a
series of progressive histologic abnormalities that include ef-
facement of glomerular epithelial cell (GEC) foot processes,
expansion of the mesangial matrix, focal denudation of areas of
the glomerular basement membrane (GBM), and eventually
glomerular sclerosis/hyalinosis. The functional correlates to these
morphologic changes are progressive azotemia, hypertension,
and proteinuria, all of which are well recognized components of
clinical end-stage renal disease (ESRD). Some progressive
glornerular disorders, in humans, include acute poststreptococ-
cal glomerulonephritis, bilateral renal cortical necrosis, and
vesiculoureteral reflux. Of note is that, in the majority of the
patients that progressed to ESRD from these initial disorders,
the underlying renal disease was quiescent, that is, there was no
ongoing immunologic injury, hypertension, or active urinary
tract infection. The authors concluded that the final common
pathway to progressive renal failure results from long-term
elevations in glomerular pressures and flows which favor hy-
perfiltration and damage the permselective properties of the
glomerular filter. Increased flux of macromolecules across the
GBM and subsequent accumulation within the mesangium
follow these untoward glomerular hemodynamic perturbations
and the impaired glomerular sieving characteristics, and may
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serve as a stimulus for proliferation of MC and overproduction
of mesangial matrix, leading eventually to glomeruloscierosis
[14].
Baldwin and Neugarten have extensively reviewed the po-
tential impact of systemic hypertension on progressive glomer-
ulopathy [15]. Basically, they contend that many nephritic
disorders are accompanied by a reduction in afferent arteriolar
resistance (RA). An elevated systemic blood pressure (SBP)
could then be transmitted to the glomerular microcirculation,
resulting in an increment in the glomerular capillary hydrostatic
pressure (PGC), leading to further hemodynamically mediated
injury [15]. There are many clinical examples of hypertension
occurring early in the course of glomerular disease much before
the volume-overloaded state of severe chronic renal insuffi-
ciency contributes to the hypertension [16, 171. However, there
is a paucity of clinical prospective, randomized, controlled
studies where both the sample size is large enough and the
methodology exact (such as, drug regimens, diet, etc.) to
properly examine this question. Therefore, in order to more
reliably explore these postulated mechanisms, investigators
have turned to experimental models of glomerular injury.
Neugarten et al [18] demonstrated in NSN, a rat model for
antiglomerular basement membrane disease, that the superim-
position of two kidney/one clip hypertension aggravated the
underlying glomerular disease as manifested by increments in
proteinuria and the percentage of glomeruli demonstrating
glomerular proliferation and glomerulosclerosis as compared to
normotensive controls with NSN. As a corollary to this, control
of systemic hypertension should ameliorate this progression to
FSGS, Neugarten et al [19] superimposed hypertension on
NSN by subjecting the rats to a unilateral nephrectomy and
allowing them to drink only 0.9% sodium chloride. One group of
these hypertensive rats with NSN was then treated with a
combination of reserpine/hydralazine/hydrochlorothiazide in the
drinking water. Significant reduction of systolic blood pressure
from 151 10 mm Hg to 104 4 mm Hg markedly improved
the clinical (24-hour proteinuria, serum albumin, heart weight)
and histologic manifestations of this hypertensive form of
glomerulonephritis. In addition, micropuncture studies per-
formed revealed that the untreated hypertensive group had
significantly elevated values for PGC, single-nephron glomerular
filtration rate (SNGFR), and glomerular capillary plasma flow
rate (QA), while treatment of the systemic hypertension normal-
ized all of these parameters. The authors concluded that the
decreased severity of vascular and glomerular injury in ne-
phritic animals was due to treatment of the systemic hyperten-
sion with a resultant reduction in glomerular hydraulic stress.
However, other investigators have not been able to demon-
strate that lowering SBP with the above-mentioned triple-drug
regimen reduces P0c [20, 21]. Anderson, Rennke and Brenner
[20], using the renal ablation model, compared the outcomes in
one and two-thirds nephrectomized rats receiving either no
therapy, triple-drug therapy (reserpine/hydralazine/hydrochloro-
thiazide), or enalapril for the systolic hypertension that accom-
panies this degree of loss of renal mass. The authors noted that
both antihypertensive regimens normalized blood pressure;
however, only the enalapril-treated group and not the triple-
drug regimen group had a significant reduction in the mean
glomerular transcapillary hydraulic pressure difference (P). In
addition, despite equivalent SBP control in both treatment
groups, failure of the triple-drug regimen to control glomerular
hypertension was associated with progressive proteinuria and
glomerular lesions comparable to those seen in untreated ne-
phrectomized rats. The conclusion drawn from this study was
that, unless glomerular capillary hypertension is corrected,
control of SBP by itself is insufficient to prevent progressive
renal injury in rats with reduced renal mass. Dworkin, Feiner
and Randazzo [21] confirmed the above findings in another
model of progressive glomerular injury, uninephrectomy with
desoxycorticosterone-salt (DOC-salt) hypertension. In that study,
uninephrectomized rats were made hypertensive by weekly
subcutaneous desoxycorticosterone injections and 1% saline
for drinking. Rats received either no therapy or triple-drug
therapy with reserpine/hydralazine/hydrochlorothiazide. Micro-
puncture studies revealed that, despite control of mean arterial
blood pressure, the triple-drug regimen failed to normalize POC.
Protein excretion and histological abnormalities in the treated
group were of comparable magnitude to the untreated group.
Again, intrarenal hypertension may persist despite normaliza-
tion of SBP and that treatment which successfully lowers only
mean arterial pressure and not Pc may be ineffective in
preventing the development of progressive glomerular abnor-
malities [21].
Dietary protein restriction, as well as converting enzyme
inhibition [20, 22, 23], has been utilized as a maneuver to lower
Poc in an attempt to prevent the development of FSGS.
Hostetter et al [24] showed that a 6% dietary protein restriction
in 1-5/6 nephrectomized animals produced significant decre-
ments in urine protein excretion, PGC. P, SNGFR, and QA as
well as a marked diminution in the histologic abnormalities that
were observed in the standard diet (24% protein) group.
Neugarten et al [25] noted, in the NSN model, that nephritic
rats on a 57.5% protein diet manifested heavy proteinuria,
hypoalbuminemia, hypercholesterolemia, azotemia, and ele-
vated serum creatinine levels. In another cohort of rats, sub-
jected to 4.6% casein, proteinuria remitted completely, and
progressive renal disease never developed. Likewise, studies
by Zatz et al [26] and Wen, Huang and Moorty [27] demon-
strated in streptozotocin-induced diabetic rats that dietary
protein restriction, ranging from 6% to 12%, significantly ame-
liorated the histologic lesion of FSGS as well as urinary albumin
excretion. Both studies postulated that reductions in glomerular
flows and pressures were responsible for this protection. Zatz
et al [26] clearly exhibited, by micropuncture, significant reduc-
tions in SNGFR, QA, and P independent of the metabolic
control of the underlying diabetes mellitus.
In our laboratory, we have been utilizing the chronic
aminonucleoside nephrosis model, in Sprague—Dawley rats,
that progresses to FSGS 18 weeks after a single intravenous
dose of puromycin aminonucleoside (PA) [28]. This model has
several attractive analogies to human glomerular disease and
some important distinctions from other experimental models of
glomerular injury. First, it is a toxin-induced glomerulopathy in
which oxygen free radical formation may play an important role
in the development of GEC injury and acute nephrosis [29].
Therefore, it represents a form of chemically-mediated renal
injury rather than a surgical removal of the vast bulk of renal
mass, and may be more analogous to an environmental or
pharmaceutical causation of glomerular injury. Secondly, the
temporal course of chronic aminonucleoside nephrosis bears
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much similarity, albeit truncated, to clinical glomerular dis-
eases. The onset of acute nephrosis occurs six to seven days
after drug administration with a peaking of the proteinuria at ten
to fourteen days. This is followed by a gradual return toward
baseline of daily urine protein excretion at four to six weeks
after PA administration; however, a recurrence of heavy pro-
teinuria with histologic evidence of FSGS develops eighteen
weeks after the initial drug delivery [28]. This course is
reminiscent of several patients with post-streptococcal glomer-
ulonephritis [30] where, following the initial glomerular inflam-
mation, there is a quiescent period where renal disease is
inapparent only to recur with the re-emergence of hypertension,
heavy proteinuria, clinical renal dysfunction and FSGS on
histologic examination. Thirdly, chronic aminonucleoside neph-
rosis is a non-hypertensive model of experimental glomerular
disease. This removes an important pathophysiologic process,
namely, systemic hypertension from the underlying cause for
this progressive disorder.
Because of the lack of systemic hypertension in chronic
aminonucleoside nephrosis and previous studies [31, 32] dem-
onstrating low SNGFR and QA, hyperfiltration/hyperperfusion
was not thought to be present, suggesting that hydraulic stress
in the glomerular microcirculation was not an important factor
in the development of this glomerulopathy. However, these
micropuncture measurements were obtained early during the
course of aminonucleoside nephrosis, when profound reduc-
tions in glomerular ultrafiltration coefficient (Kf) overshadowed
the other hemodynamic parameters. In an attempt to address
this question in chronic aminonucleoside nephrosis, we have
observed that a 6% dietary protein restriction conferred both
functional and histologic protection 18 weeks after PA admin-
istration [33]. Since studies in other models have shown a
reduction in PGC after instituting dietary protein restriction [24,
26], a role for glomerular capillary hypertension in the patho-
genesis of progressive glomerular damage in chronic aminonu-
cleoside nephrosis can be inferred. In order to confirm this,
Anderson et al [34], have recently found, using micropuncture
techniques in Munich-Wistar rats with chronic aminonucleoside
nephrosis, that, at nine weeks after PA administration, during
apparent clinical recovery from acute glomerular injury, gb-
merular capillary hypertension developed and accompanied the
normalization of SNGFR and K1 which were both significantly
reduced during acute nephrosis. The authors contended that the
emergence of glomerular capillary hypertension at a time when
acute nephrosis had completely resolved, may explain the
subsequent development of FSGS in this model [34]. However,
Fogo et al [35] have challenged this hypothesis since they found
no specific abnormal glomerular hemodynamics which could be
incriminated for the subsequent glomerular structural damage
in chronic aminonucleoside nephrosis.
Cell-mediated proliferation
The "response to injury" hypothesis in atherosclerosis in-
cludes a potential role for macrophages and/or platelets to
accumulate at injured endothelial sites and release factors (that
is, PDGF, fibroblast growth factor, epidermal growth factor)
that may allow the atherosclerotic lesion to progress via VSMC
proliferation [36]. In this process, the macrophages, after ad-
hering to the endothelium, penetrate into the intima and become
lipid laden (foam cells) since receptors for both native and
modified LDL are present on the cell surface [37]. This aggre-
gate of foam cells constitutes the forerunner of the fatty streak
[36]. As the lesion continues to evolve, VSMC also migrate into
the intima and proliferate while becoming filled with lipid [36].
The platelet and/or macrophage products, mentioned above,
may play a vital role in this VSMC proliferative process, and,
with time, foci of necrosis and inflammation characteristic of
the fibrous plaque develops [36].
In the glomerulus, a similar mechanism in regards to macro-
phage infiltration may be involved since Schreiner et al [38, 39]
have demonstrated an increase in the number of Ia-bearing,
macrophage-like MC in both the NSN and aminonucleoside
nephrosis models. Interestingly, in NSN, the presence of gb-
merular macrophages has been shown to be related to increased
proteinuria, perhaps due to the potent biologic activity of
macrophage secretions [39]. These cell products, as in the
atherosclerotic process, may exert a proliferative stimulus on
glomerular mesangial cells, which possess smooth muscle-like
characteristics [12], enabling the incipient FSGS lesion to
progress.
Lipid-induced proliferation
In the atherosclerotic process, diet-induced hypercholester-
olemia and, more specifically, elevated LDL, may be an initi-
ating factor for endothelial injury [36]. More importantly,
VSMC may also possess receptors for LDL, thereby enabling
the intracellular accumulation of lipid and the appearance as
foam cells [36]. Although only LDL is consistently found in
human lesions, a wider variety of lipoprotein species, including
VLDL and remnant particles, are atherogenic in experimental
animals. In regards to a stimulatory capacity of lipoproteins on
VSMC growth, Fischer-Dzoga and Wissler [40] have demon-
strated that hyperlipemic serum, when it replaced normal serum
in the tissue culture media, induced proliferation of VSMC in
the monkey, as measured by 3H-thymidine incorporation and
increase in culture area. LDL had the greatest effect, while
HDL had no effect. Also, Ross and Gbomset [41] have demon-
strated similar stimulatory effects on arterial smooth muscle cell
growth when lipoprotein fractions were added to the medium.
LDL had a greater growth-promoting effect than HDL, even
when the concentrations of lipoprotein cholesterol were equal.
The authors postulated that certain cells can use lipoprotein
cholesterol to form membranes and that the rate of biosynthesis
of membrane cholesterol may limit cell proliferation [41]. It
should be noted, however, that the proliferative events could be
due to causes other than hyperlipidemia; and once the prolifer-
ative lesion is in place, the presence of hyperlipidemia leads to
deposition of lipid macromolecules with deleterious conse-
quences.
Recently, Moorhead et al [42] have speculated that abnor-
malities in lipid metabolism may play a central role in the
progression of initial gbomerular injury to FSGS. Briefly, this
theory rests on observations that, following glomerular injury,
there is increased lipoprotein synthesis and decreased lipopro-
tein catabolism. In the former instance, declines in oncotic
pressure secondary to albuminuria may be a potent stimulus for
hepatic lipoprotein synthesis [43]. In regards to the decreased
catabolism of lipoprotein precursors, de Mendoza et al [44]
have noted increased high-density lipoprotein (HDL) in the
urine of rats with aminonucleoside nephrosis and that the urine
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also activated an in vitro lipoprotein lipase system. The authors
speculated that urinary loss of lipoprotein lipase activator, such
as apoprotein C-Il may lead to persistence of hyperlipidemia
because of decreased clearing of chylomicra and triglycerides
from the circulation. Increased circulating levels of lipoproteins
could be potentially nephrotoxic in the following manner. First,
at physiologic pH, VLDL and LDL are capable of binding with
polyanionic glycosaminoglycans [451. Theoretically, this could
further neutralize glomerular anionic moieties, which have
already been reduced by the initial glomerular injury in certain
models (that is, aminonucleoside nephrosis), thereby worsening
the charge-selective defect in the glomerular filter with en-
hanced permeability of macromolecules into the mesangium
[46, 47]. Secondly, penetration of the injured glomerular base-
ment membrane occurs, and even the relatively large size of
LDL could not impair the diffusion of the substance [42, 48].
Once lipoproteins gain access to the glomerular mesangium,
they could bind to mesangial cells (MC) if they possess recep-
tors as do macrophages [491, which one subpopulation of MC is
derived from, allowing the intracellular accumulation of excess
lipids. Since MC are similar to vascular smooth muscle cells
(VSMC) in terms of origin [4], contractility [61, myoid chemical
and structural characteristics [5], and inhibition of growth in
response to exogenously administered heparin compounds [9,
10], they may also respond in an analogous fashion, after
presentation of excess lipid to them, with proliferation and
production of excess matrix substance, both of which are
pathologic harbingers of FSGS [141. Studies addressing this
issue are presently underway.
We have recently demonstrated that maintaining rats on a 4%
cholesterol/l% cholic acid diet, which produces hypercholes-
terolemia without hypertriglyceridemia, after initiating amino-
nucleoside nephrosis, results in a significant elevation in urine
protein excretion, a decline in whole-kidney GFR, and more
prevalent histologic features of FSGS at eighteen weeks after
PA delivery, including a marked increment in the percentage of
glomeruli with mesangial foam cells. This suggests that alimen-
tary hypercholesterolemia selectively aggravates glomerular
injury and the subsequent development of FSGS in this model
[50]. Lipoprotein electrophoresis of sera from rats fed this
dietary cholesterol supplement reveals a very prominent beta-
band as compared to normal diet controls [51]. This lipoprotein
had a cholesterol-to-triglyceride ratio of approximately 60:1
[511. Lassler et al [52] noted in rats fed a similar cholesterol-
supplemented diet that the serum VLDL concentration was
very high and that the composition of this lipoprotein was
different from that of normal animals in its disproportionate
increase in cholesterol content. In addition Kasiske et al [53]
have demonstrated that the lipid-lowering agent, clofibric acid,
ameliorates renal injury in the ablation model independent of
glomerular hemodynamics [54], Recently, these workers have
also shown that the cholesterol synthesis inhibitor, mevinolin,
reduces glomerular injury in the rat following extensive loss of
renal mass [55]. Alternatively, Grond, Weening and Elema [56]
have demonstrated by utilizing the chronic adriamycin and
aminonucleoside nephrosis models, that, despite comparable
serum levels of cholesterol and triglycerides, the glomeruli of
PA rats showed significantly greater accumulation of lipid
within the mesangium as well as glomerulosclerosis lesions as
compared to adriamycin-treated animals. The authors con-
eluded that, in chronic aminonucleoside nephrosis, increased
mesangial activity as evidenced by the increased accumulation
of macromolecular substances (that is, lipids) may lead to
eventual sclerosis. As a corollary, the mesangial activity in
adriamycin nephrosis was normal, suggesting that the evolution
to glomerulosclerosis may be a function of augmented mesan-
gial activity rather than just simply elevated serum lipid levels
[56]; this would be in accord with the idea that proliferation, per
se, may not be secondary to hyperlipidemia, but can be due to
other causes. The hyperlipidemia, then, can lead to deposition
of lipid macromolecules within the glomerular lesion, leading to
deleterious effects.
Coagulation and thrombosis
Thrombosis may be an important pathogenic factor, in cer-
tain vascular beds, during the later stages of the atherosclerotic
process. Two lines of clinical evidence from patients with
myocardial infarction exist supporting a role for thrombosis in
aggravating the atherosclerotic process. First, there are ana-
tomic and pathologic studies that document the presence of a
thrombus in a very high proportion of patients with myocardial
infarction [57]. The second line of evidence suggesting that
thrombosis is important in the pathogenesis of myocardial
infarction comes from successful case studies of intracoronary
streptokinase treatment in achieving reperfusion of the oc-
cluded vessel [58]. In the glomerular microcirculation, glomer-
ular capillary hypertension is also capable of damaging the
endothelium, and this purportedly can activate platelets and
result in glomerular thrombosis [59].
/J'ects of thromboxane and prostacyclin
A great deal of data has been generated about the prostaglan-
dins and their metabolites in regards to a crucial role in the
physiologic actions of platelets, endothelium, and vascular
smooth muscle in the atherogenic process. Thromboxane A2,
primarily formed by the platelet, is a powerful vasoconstrictor
capable of stimulating VSMC contraction and platelet aggrega-
tion. It has a short half-life and is spontaneously converted to a
stable metabolite, thromboxane B2. Prostacyclin (PGI7) is the
principal product of cyclooxygenase activity in the walls of
arteries and veins. PGI, is synthesized from arachadonic acid
by the endothelium and VSMC and is an extremely potent
vasodilator as well as an inhibitor of platelet aggregation.
Prostaglandin biosynthesis may be important not only in
thrombosis (in terms of platelet adherence and aggregation) but
also in modifying the atherosclerotic process by formation of
PGI2. Also, interference with thromboxane A7 generation with
marine oils (such as, eicosapentaenoic acid) may be important
in protection against atherosclerosis, either through platelet
inhibition or directly against the disease process [60].
Recently, Donadio et al [61] demonstrated the efficacy of
dipyridamole and aspirin therapy in preserving GFR in patients
with Type I membranoproliferative glomerulonephritis. Exper-
imental work has been conducted on the use of anti-platelet
agents in the renal ablation model in an attempt to understand
both the role of platelet activation on the course of progressive
glomerulopathy. Purkerson et al [591 examined the potential
role of endogenous thromboxane on the progression of renal
disease in rats with reduced renal mass by utilizing a selective
oral inhibitor of thromboxane synthesis (OKY 1581). It was
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noted that chronic oral administration of OKY 1581 decreased
urine protein and thromboxane excretion, lowered blood pres-
sure, improved renal histology, and, interestingly, increased QA
and SNGFR. This latter observation suggests that the efficacy
of this agent is unrelated to favorable reductions in glomerular
hemodynamic parameters. The authors concluded that, in this
model, platelet aggregation leading to intraglomerular thrombo-
sis plays a key role in the development of glomerulosclerosis.
Effects ofheparin and heparinoid compounds
Purkerson, Hoffsten and Klahr [621 demonstrated in nephrec-
tomized rats, that commercial heparin treatment significantly
lowered blood urea nitrogen concentrations, blood pressures,
and the proportion of abnormal glomeruli on light microscopy.
In a related study, heparin's protection correlated with a
marked and sustained prolongation of the activated partial
thromboplastin time (PTT), prothrombin time (PT). as well as a
transient prolongation of the bleeding time [63]. Also, adminis-
tration of coumadin at doses which caused a significant prolon-
gation of the PT and the bleeding time, inhibited the develop-
ment of progressive hypertension and uremia in rats with
experimental partial renal infarction [63]. It was contended that
this data supported the concept that glomerular thrombosis
plays an important role in the pathogenesis of progressive
glomerulopathy, although the mechanisms by which activation
of the blood coagulation system is triggered in response to renal
infarction remains unclear. Olson [64] studied the effects of two
different heparin compounds, whole heparin (WH) and a low
molecular weight fraction of heparin, on the progression of
glomerular disease in 1-5/6 nephrectomized rats. Whole hepa-
rin-treated animals had a prolonged clotting time, reduced
blood pressure elevation, elimination of albuminuria, and less-
ening of renal damage on histologic evaluation. No such differ-
ences were observed in the rats receiving the fraction of heparin
or the control group which received no therapy. It was specu-
lated that, in addition to inhibiting the intrinsic coagulation
cascade factors, heparin may also have inhibited another serine
protease, renal kallikrein. resulting in a diminution in renin
generation culminating in a reduction of SBP and/or an alter-
ation in renal hemodynamics. The lack of an effect on blood
pressure by the fraction of heparin does raise the possibility of
a beneficial antihypertensive effect; however, in regards to
glomerular hemodynamic alterations, Ichikawa et al [65] have
recently demonstrated, in this same model by using micropunc-
ture techniques, that there were no differences in SNGFR, PGC,
or QA between heparin- and non-heparin-treated nephrecto-
mized rats. It was concluded that the effect of heparin in
protecting glomeruli from structural damage is mediated by a
mechanism independent of Pç [65].
We have recently shown that a nonanticoagulant heparin
compound (prepared by passage through an ion-exchange chro-
matographic column) and whole heparin. in a dose not sufficient
to prolong the activated PTT. both ameliorated the functional
and histologic abnormalities in chronic aminonucleoside nephro-
sis [661. The protection conferred was not related to a reduction
in blood pressure since this is a normotensive model of progres-
sive glomerular disease. Extrapolating from the micropuncture
data in the ablation model [65], and the absence of either
antihypertensive or anticoagulant effects, we believe that
heparin may protect the kidney through an antiproliferative
effect on glomerular MC analogous to heparin's antiprolifera-
tive effect on VSMC. It has been previously demonstrated by
other members of this laboratory using both an in vivo vessel
wall injury model [7, 81 and in tissue culture [9, 10] that whole
heparin inhibits VSMC proliferation. Castellot et al [Ill have
recently studied whole heparin, nonanticoagulant heparin, and
a low molecular weight heparin fragment on glomerular MC
proliferation in vitro. Upon comparison of these three heparin
compounds (which were all utilized in the chronic aminonucle-
oside nephrosis study [66]), both the nonanticoagulant and
whole heparin compounds produced a 50 to 55% growth inhi-
bition of cultured MC in vitro, as compared to the 25 to 30%
growth inhibition for the heparin fragment compound. We
believe that the greater inhibitory effect of the nonanticoagulant
and whole-heparin compounds on glomerular MC in vitro may
explain the efficacy of these two heparin moieties in conferring
functional and histologic protection in the chronic aminonucle-
oside model, whereas the heparin fragment possessing the least
inhibitory capacity was ineffective [661.
Summary
In summary, both the developing atherosclerotic and FSGS
lesions seem to share certain postulated pathophysiologic
mechanisms, including endothelial cell injury, macrophage in-
filtration, hyperlipoproteinemia, and hypertension. As depicted
in Figure 1, any initial glomerular injury results in flux of
macromolecular substances into the glomerular mesangium. As
an adjunct to increased glomerular barrier dysfunction, hyper-
lipoproteinemia is believed to secondarily develop from the
dramatic losses of albumin, stimulating increased hepatic lipo-
protein synthesis [42, 43] and the loss of lipoprotein lipase-
activating substance into the urine which would effectively
produce a reduction in circulating chylomicra and triglyceride
catabolism [44]. Certain elevated circulating lipoproteins could,
theoretically, pass through the damaged glomerular filter into
the mesangium [42], thereby enhancing the flux of macromol-
ecules. Also associated with certain experimental glomerular
disorders is the development of glomerular hypertension, as
manifested by an elevated glomerular capillary hydrostatic
pressure (P0c), which can further augment macromolecular flux
into the mesangium [19, 20, 24, 26]. Overloading of the glomer-
ular mesangium by the above mechanisms is believed to be an
injurious stimulus for MC to both proliferate and produce
excess mesangial matrix substance. Both of these events are
thought to be pathologic harbingers of glomerulosclerosis [14].
Glomerular hypertension is also capable of damaging endothe-
hal cells within the glomerular microcirculation, and this pur-
portedly can activate platelets and result in glornerular throm-
bosis [59]. At present, it is unclear how glomerular thrombosis
produces increased mesangial cell injury; however, this process
is believed to cause both systemic and glomerular hypertension
which may serve as intermediary mechanisms producing the
untoward effects of mesangial cell proliferation and matrix
overproduction [59].
Unsolved questions and new directions
Many unanswered questions and intriguing observations ex-
ist that would further link the two pathophysiologic processes.
One must question whether hyperlipidemia is a direct cause of
glomerulosclerosis. French, Yamanka and Ostwald [67] have
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Fig. 1. A schema of possible pathogenic
events involved in the development of
glomerulosclerosis following initial glomern/ar
injury
noted that guinea pigs made anemic and fed a 1% cholesterol
diet developed a glomerular lesion identical to FSGS. However,
in humans, although there is no direct causal relationship
between hyperlipidemia or advanced arteriosclerosis as precur-
sors of FSGS, Kasiske and Crosson [68] have recently noted
that the predominant glomerular lesion in morbidly obese
patients undergoing renal biopsy was FSGS. The authors pos-
tulated that, since hypercholesterolernia and hypertriglyceride-
mia are common in obesity, it is possible that abnormalities in
lipid metabolism may contribute to the development of glomer-
ular injury. Interestingly, Weisinger et al [691 observed that, in
four patients with nephrotic syndrome as a complication of
massive obesity, dietary restriction was accompanied by weight
loss and simultaneous remission in proteinuria and the ne-
phrotic syndrome. Clearly, further clinical studies need to be
conducted to further establish whether such a causal relation-
ship between hyperlipidemia and glomerular abnormalities
exists. Also, since patients with nephrotic syndrome have
abnormalities in lipid metabolism, the effects of dietary and
pharmacologic intervention to reduce circulating lipid levels on
the course of the underlying renal disease needs to be thor-
oughly evaluated as a potential means to retard the progression
to ESRD.
From the experimental perspective, the altered cell biology of
the MC in response to lipid-enriched media warrants examina-
tion. Changes in MC growth regulation, matrix biosynthesis,
and phagocytosis after exposure to elevated lipid levels need to
be assessed. In addition, interactions between circulating and!
or glomerular macrophages and glomerular MC, as it relates to
MC growth and function, needs to be studied since "process-
ing" of the lipid by macrophages may have to occur prior to
direct effects on the MC. In all, many of the advances in our
understanding of the atherosclerotic process needs to be ap-
plied to progressive glomerulopathy, since many similarities
exist suggesting an analogous pathophysiologic basis.
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